Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)

ConclusionThe addition of cituxumumab to lapatinib and capecitabine did not improve PFS or OS compared with lapatinib and capecitabine in patients with HER2-positive MBC.Clinical trial registryClinicalTrials.gov Identifier: NCT00684983
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research